Results 231 to 240 of about 3,543,538 (259)

Cutaneous Adverse Drug Reactions Associated With BRAF and MEK Inhibitors: A Real‐World Analysis of WHO Pharmacovigilance Data

open access: yesClinical Pharmacology &Therapeutics, Volume 120, Issue 1, Page 274-285, July 2026.
BRAF inhibitors and MEK inhibitors (MEKi) have reshaped the treatment of BRAFV600‐mutant malignancies; however, cutaneous adverse drug reactions (ADRs) remain a frequent and clinically impactful toxicity. Although clinical trials provide insight into their safety profiles, real‐world data on dermatologic ADRs are limited.
Natalia Sauer   +3 more
wiley   +1 more source
Some of the next articles are maybe not open access.

Related searches:

Recent advances in keratin for biomedical applications

Advances in Colloid and Interface Science, 2023
Yushuang Shang, Jiang Yuan
exaly  

Home - About - Disclaimer - Privacy